Anand Patel, MD, of the University of Chicago, discusses results from a phase II trial that showed tyrosine kinase inhibitor plus inotuzumab ozogamicin–based therapy resulted in major molecular response in patients newly diagnosed with Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) (Abstract 441).
Ibrahim Aldoss, MD, of City of Hope, presents findings from a small, single-center study of patients aged 55 years and older with B-cell acute lymphoblastic leukemia (ALL) in first complete remission who were treated with CD19-directed CAR T-cell therapy. Researchers found the therapy was safe, resulted in low-grade adverse events, and led to preliminary durable measurable residual disease response (Abstract 443).
Alexander Lesokhin, MD, of Memorial Sloan Kettering Cancer Center, discusses results of a retrospective analysis from the phase II MagnetisMM-3 trial. A post hoc analysis was conducted of the subgroup of patients enrolled in the study who had a prolonged treatment interruption or who permanently discontinued elranatamab and maintained their responses for 6 months or longer (Abstract 2269).
Jennifer Woyach, MD, of The Ohio State University Comprehensive Cancer Center, discusses results from the first head-to-head comparison of pirtobrutinib vs ibrutinib in treatment-naive patients and patients with covalent Bruton tyrosine kinase inhibitor–naive relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (Abstract 683).
Jayastu Senapati, MBBS, of The University of Texas MD Anderson Cancer Center, presents initial results from a phase II trial of brexucabtagene autoleucel as consolidation therapy in front-line high-risk B-cell acute lymphoblastic leukemia (B-ALL) or relapsed/refractory B-ALL after cytoreduction (Abstract 1573).
Krina Patel, MD, MSc, of The University of Texas MD Anderson Cancer Center, provides updated results from the fully enrolled, ongoing iMMagine-1 phase II registrational trial of anitocabtagene autoleucel, an autologous anti-BCMA CAR T-cell therapy with a novel D-domain binder. The agent is under development for patients with relapsed and/or refractory multiple myeloma (Abstract 256).
